pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·3h ago·1 min read
save

Metriport secures $26 million Series A to streamline doctor access to patient data

Aug 27, 2026·read at Endpoints ↗DealPositive

Metriport, a health-tech startup focused on simplifying how physicians obtain patient information, announced a $26 million Series A financing.

The round was led by Matrix, with participation from ARTIS and Y Combinator. The capital will be used to expand the platform's capabilities and grow its team.

Co-founders Dima Goncharov (CEO) and Colin Elsinga (COO) said the funding will accelerate efforts to integrate with electronic health-record systems and improve data retrieval speed for clinicians.

The investment reflects growing investor interest in tools that reduce administrative burdens in healthcare and could position Metriport for broader adoption across medical practices.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Metriport raises $26M to help doctors retrieve patient data”

read at Endpoints ↗
92 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 36m agoQ&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big dealEndpoints
  • 1h agoLilly's move to hide Phase 1 pipeline draws mixed reviewsEndpoints
  • 1h agoModerna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 winsEndpoints
  • 1h agoWhy one venture investor is going from 'studio' to 'firm'Endpoints
  • 1h agoRayzeBio's $173M radiopharma plan; Lonza creates commercial chief positionEndpoints